Kenneth Kousky - Gemphire Therapeutics Independent Director
Director
Mr. Kenneth Kousky is Independent Director of the Company. Mr. Kousky has served as the Chief Executive Officer of the MidMichigan Innovation Center, a privately funded, nonprofit business incubator, since 2010. He has also served as the President and Chief Executive Officer of IP3, Inc., an information security consulting firm, since 2002. Also, Mr. Kousky is a founding member and has served as Executive Director of the Blue Water Angels Investment Network, a Michiganbased funding network that assists in private equity investments in earlystage tech startups, since 2008. In 1988, Mr. Kousky founded an IT services company, Wave Technologies International Inc., which he led through an initial public offering in 1994. In 1989, he established Washington University graduate program in Telecommunication Management, and he has lectured at Saginaw Valley State University, Washington University and at the Wharton School of Business at the University of Pennsylvania. Mr. Kousky is a member of several corporate boards, including Michigan Sugar Company, RetroSense Therapeutics LLC and Foodjunky LLC since 2015.
| Age | 63 |
| Tenure | 9 years |
| Phone | 734-245-1700 |
| Web | http://www.gemphire.com |
Gemphire Therapeutics Management Efficiency
The company has return on total asset (ROA) of (44.9) % which means that it has lost $44.9 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (280.97) %, meaning that it created substantial loss on money invested by shareholders. Gemphire Therapeutics' management efficiency ratios could be used to measure how well Gemphire Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Loreto Silva | Barrick Gold Corp | 55 | |
| Charles Hodges | WPP PLC ADR | 62 | |
| Jeanine Lioko | Barrick Gold Corp | 52 | |
| Gary Ginsberg | Townsquare Media | 58 | |
| Bonnie Lind | US Silica Holdings | 60 | |
| Karl Voltaire | Barrick Gold Corp | 63 | |
| Diane Duren | US Silica Holdings | 61 | |
| Zhang YaQin | WPP PLC ADR | N/A | |
| John Stauch | Deluxe | 56 | |
| Joanne Wilson | WPP PLC ADR | 49 | |
| Peter Bernard | US Silica Holdings | 59 | |
| Ranjana Singh | WPP PLC ADR | N/A | |
| B Stanley | WT Offshore | 66 | |
| Daniel Avramovich | US Silica Holdings | 62 | |
| George Murphy | WPP PLC ADR | 62 | |
| Tarek Farahat | WPP PLC ADR | 55 | |
| Shangning Qian | Yuexiu Transport Infrastructure | 51 | |
| Tom Waldron | WPP PLC ADR | N/A | |
| Steven Shapiro | Barrick Gold Corp | 65 | |
| Ernie Thrasher | Barrick Gold Corp | 61 | |
| Olivia Kirtley | Barrick Gold Corp | 66 | |
Management Performance
| Return On Equity | -280.97 | |||
| Return On Asset | -44.9 |
Gemphire Therapeutics Leadership Team
Elected by the shareholders, the Gemphire Therapeutics' board of directors comprises two types of representatives: Gemphire Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gemphire. The board's role is to monitor Gemphire Therapeutics' management team and ensure that shareholders' interests are well served. Gemphire Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gemphire Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Bisgaier, Co-Founder, Chief Scientific Officer | ||
| Mina Sooch, President CEO | ||
| Kenneth Kousky, Independent Director | ||
| Andrew Sassine, Independent Director | ||
| Jeffrey Mathiesen, CFO | ||
| Seth Reno, Chief Commercial Officer | ||
| Pedro Lichtinger, Independent Director | ||
| Steven Gullans, Interim President Interim CEO, Director | ||
| David Lowenschuss, Co-Founder, Chief Legal Officer | ||
| Kent Hawryluk, Independent Director | ||
| Lee Golden, Chief Medical Officer |
Gemphire Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gemphire Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -280.97 | |||
| Return On Asset | -44.9 | |||
| Current Valuation | 109.69 M | |||
| Shares Outstanding | 14.87 M | |||
| Shares Owned By Insiders | 55.90 % | |||
| Shares Owned By Institutions | 17.95 % | |||
| Number Of Shares Shorted | 142.79 K | |||
| Price To Earning | (2.89) X | |||
| Price To Book | 2.46 X | |||
| EBITDA | (12.09 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Gemphire Stock
If you are still planning to invest in Gemphire Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gemphire Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |